Association of Antidepressant and/or Benzodiazepine Use With Cannabis Frequency and Differences by Sex in Primary Care Patients With Depression and/or Anxiety
Open Access
- 1 January 2026
- journal article
- Published by Wiley in Depression and Anxiety
- Vol. 2026 (1)
Abstract
Background: Cannabis use is increasingly prevalent among adults with depression and anxiety, raising concerns about potential interactions with prescribed antidepressant medication and/or benzodiazepines. Using data from a large, university health system in Los Angeles, this cross‐sectional study examined the association between having an active prescription of antidepressant medication and/or benzodiazepines and frequency of cannabis use by sex in adult primary care patients with depression and/or anxiety. Methods: This analysis included 45,693 adult male and female patients with a current diagnosis of depression and/or anxiety (International Classification of Diseases, Tenth Revision [ICD‐10] codes: F41, F33) listed in their electronic health record (EHR). Among patients with a diagnosis, those with an active prescription for antidepressant medication and/or benzodiazepines were identified using EHR data. Cannabis use was assessed as part of routine patient self‐administered screening via the EHR‐based Tobacco and Cannabis Questionnaire (TCQ) from January 2021 to June 2023. Sex‐stratified multivariable ordinal logistic regression models assessed whether active antidepressant medication and/or benzodiazepine prescriptions were associated with increased cannabis use frequency. Models were adjusted for sexual identity, age, race/ethnicity, employment, and Charlson Comorbidity Index (CCI). Results: Females comprised 67.5% of the sample of patients with depression and/or anxiety; 16.3% reported cannabis use for mental health symptoms. Cannabis use for mental health symptoms among males was 21.2%.Among those with depression and/or anxiety, 46.2% of females and 42.8% of males were prescribed antidepressant medication and/or benzodiazepines. Females with an active prescription for antidepressant medication and/or benzodiazepines had 1.32 times the adjusted odds of more frequent cannabis use (95% CI: 1.24–1.40) compared to those without a prescription. Among males, the adjusted odds ratio was lower at 1.14 (95% CI: 1.06–1.23), suggesting a significant difference by sex. Conclusions: Findings indicate that cannabis use commonly occurs alongside prescribed mental health treatment, underscoring the need for primary care providers to routinely address cannabis and medication co‐use during clinical care.Keywords
This publication has 43 references indexed in Scilit:
- Cannabis Laws and Utilization of Medications for the Treatment of Mental Health DisordersJAMA Network Open, 2024
- Cannabis Use Reported by Patients Receiving Primary Care in a Large Health SystemJAMA Network Open, 2024
- Prevalence of Cannabis Use Disorder and Reasons for Use Among Adults in a US State Where Recreational Cannabis Use Is LegalJAMA Network Open, 2023
- Nondisordered Cannabis Use Among US AdolescentsJAMA Network Open, 2023
- Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive ReviewJournal of General Internal Medicine, 2021
- Association of Depression With Past-Month Cannabis Use Among US Adults Aged 20 to 59 Years, 2005 to 2016JAMA Network Open, 2020
- New trends in cannabis potency in USA and Europe during the last decade (2008–2017)European Archives of Psychiatry and Clinical Neuroscience, 2019
- Cannabis and mental illness: a reviewEuropean Archives of Psychiatry and Clinical Neuroscience, 2018
- Predictive validity of cannabis consumption measures: Results from a national longitudinal studyAddictive Behaviors, 2017
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987